Addisons disease therapeutics market size to increase by USD 442 million: 41% growth to originate from North America - Technavio

NEW YORK, Dec. 14, 2022 /PRNewswire/ -- The Addisons Disease Therapeutics Market by Therapy, End-user, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 6.93% and register an incremental growth of USD 442 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download A PDF Sample Report.

Regional Analysis

By region, the global Addisons disease therapeutics market is segmented into North America, Europe, Asia, and the Rest of the World (ROW). North America will account for 41% of the market's growth during the forecast period. The availability of reimbursement policies is driving the growth of the regional market.

Company Profiles

The Addisons disease therapeutics market report includes information on the key products and recent developments of leading vendors, including:

• Akorn Operating Co. LLC:
• Amneal Pharmaceuticals Inc.
• Bristol Myers Squibb Co.
• Neurocrine Biosciences Inc.
• Hikma Pharmaceuticals Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• GlaxoSmithKline Plc
• Abbott Laboratories
• Amgen Inc.
• Eli Lilly and Co.

• To gain access to more vendor profiles available with Technavio, buy the report!

Market Dynamics

The market is driven by factors such as special drug designations, reformulation of drugs, and favorable reimbursement scenarios. However, the delayed diagnosis is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample

Market Segmentation

• By end-user, the market is segmented into hospitals, clinics, and diagnostic laboratories. The oral drugs segment accounted for the largest share of the market during the forecast period.
• By geography, the market is segmented into North America, Europe, Asia, and the Rest of the World (ROW). North America will account for 41% of the market's growth during the forecast period.

Related Reports:

The Africa HIV Treatment Drugs Market size is projected to grow by USD 321.6 million from 202 to 2027, and the market's growth momentum will accelerate at a CAGR of 3.76%. The report extensively covers market segmentation by drug class (reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, and coreceptor antagonists), route of administration (oral drugs and injectable drugs), and geography (APAC, North America, Europe, Middle East and Africa, and South America).

The Infectious Disease Market size is projected to grow by USD 104.81 billion from 2022 to 2027, and the market's growth momentum will accelerate at a CAGR of 12.49%. This report extensively covers market segmentation by product (drugs and vaccines), end-user (hospital, multispecialty clinic, and others), and geography (APAC, North America, Europe, Middle East, and Africa, and South America).

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this Addisons disease therapeutics market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Addisons disease therapeutics market between 2023 and 2027
• Precise estimation of the size of the Addisons disease therapeutics market size and its contribution of the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the Addisons disease therapeutics market industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Addison's disease therapeutics market  vendors

Browse for Technavio "Health Care" Research Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
• Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global addisons disease therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global addisons disease therapeutics market 2017 - 2021 ($ million)

• 4.2 Therapy Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)

• 4.3 End-user Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

• 6.1 Market segments 
• Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)

• 6.2 Comparison by Therapy 
• Exhibit 32: Chart on Comparison by Therapy
• Exhibit 33: Data Table on Comparison by Therapy

• 6.3 Oral drugs - Market size and forecast 2022-2027
• Exhibit 34: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)

• 6.4 Parenteral drugs - Market size and forecast 2022-2027
• Exhibit 38: Chart on Parenteral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Parenteral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Parenteral drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Parenteral drugs - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Therapy 
• Exhibit 42: Market opportunity by Therapy ($ million)

7 Market Segmentation by End-user

• 7.1 Market segments 
• Exhibit 43: Chart on End-user - Market share 2022-2027 (%)
• Exhibit 44: Data Table on End-user - Market share 2022-2027 (%)

• 7.2 Comparison by End-user 
• Exhibit 45: Chart on Comparison by End-user
• Exhibit 46: Data Table on Comparison by End-user

• 7.3 Hospitals and clinics - Market size and forecast 2022-2027 
• Exhibit 47: Chart on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Data Table on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Chart on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Hospitals and clinics - Year-over-year growth 2022-2027 (%)

• 7.4 Diagnostic laboratories - Market size and forecast 2022-2027 
• Exhibit 51: Chart on Diagnostic laboratories - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on Diagnostic laboratories - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on Diagnostic laboratories - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Diagnostic laboratories - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by End-user 
• Exhibit 55: Market opportunity by End-user ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 57: Chart on Market share by geography 2022-2027 (%)
• Exhibit 58: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 59: Chart on Geographic comparison
• Exhibit 60: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 81: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 Japan - Market size and forecast 2022-2027
• Exhibit 89: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.11 Canada - Market size and forecast 2022-2027
• Exhibit 93: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 97: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 98: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 99: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 100: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 101: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 102: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 103: Matrix on vendor position and classification

• 12.3 Abbott Laboratories 
• Exhibit 104: Abbott Laboratories - Overview
• Exhibit 105: Abbott Laboratories - Business segments
• Exhibit 106: Abbott Laboratories - Key news
• Exhibit 107: Abbott Laboratories - Key offerings
• Exhibit 108: Abbott Laboratories - Segment focus

• 12.4 Actiza Pharmaceutical Pvt. Ltd. 
• Exhibit 109: Actiza Pharmaceutical Pvt. Ltd. - Overview
• Exhibit 110: Actiza Pharmaceutical Pvt. Ltd. - Product / Service
• Exhibit 111: Actiza Pharmaceutical Pvt. Ltd. - Key offerings

• 12.5 Akorn Operating Co. LLC 
• Exhibit 112: Akorn Operating Co. LLC - Overview
• Exhibit 113: Akorn Operating Co. LLC - Product / Service
• Exhibit 114: Akorn Operating Co. LLC - Key offerings

• 12.6 Amgen Inc. 
• Exhibit 115: Amgen Inc. - Overview
• Exhibit 116: Amgen Inc. - Product / Service
• Exhibit 117: Amgen Inc. - Key offerings

• 12.7 Amneal Pharmaceuticals Inc. 
• Exhibit 118: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 119: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 120: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 121: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 122: Amneal Pharmaceuticals Inc. - Segment focus

• 12.8 Bayer AG 
• Exhibit 123: Bayer AG - Overview
• Exhibit 124: Bayer AG - Business segments
• Exhibit 125: Bayer AG - Key offerings
• Exhibit 126: Bayer AG - Segment focus

• 12.9 Bristol Myers Squibb Co. 
• Exhibit 127: Bristol Myers Squibb Co. - Overview
• Exhibit 128: Bristol Myers Squibb Co. - Product / Service
• Exhibit 129: Bristol Myers Squibb Co. - Key offerings

• 12.10 Eli Lilly and Co. 
• Exhibit 130: Eli Lilly and Co. - Overview
• Exhibit 131: Eli Lilly and Co. - Product / Service
• Exhibit 132: Eli Lilly and Co. - Key offerings

• 12.11 GlaxoSmithKline Plc 
• Exhibit 133: GlaxoSmithKline Plc - Overview
• Exhibit 134: GlaxoSmithKline Plc - Business segments
• Exhibit 135: GlaxoSmithKline Plc - Key offerings
• Exhibit 136: GlaxoSmithKline Plc - Segment focus

• 12.12 Hikma Pharmaceuticals Plc 
• Exhibit 137: Hikma Pharmaceuticals Plc - Overview
• Exhibit 138: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 139: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 140: Hikma Pharmaceuticals Plc - Segment focus

• 12.13 Merck and Co. Inc. 
• Exhibit 141: Merck and Co. Inc. - Overview
• Exhibit 142: Merck and Co. Inc. - Business segments
• Exhibit 143: Merck and Co. Inc. - Key news
• Exhibit 144: Merck and Co. Inc. - Key offerings
• Exhibit 145: Merck and Co. Inc. - Segment focus

• 12.14 Neurocrine Biosciences Inc. 
• Exhibit 146: Neurocrine Biosciences Inc. - Overview
• Exhibit 147: Neurocrine Biosciences Inc. - Product / Service
• Exhibit 148: Neurocrine Biosciences Inc. - Key offerings

• 12.15 Novartis AG 
• Exhibit 149: Novartis AG - Overview
• Exhibit 150: Novartis AG - Business segments
• Exhibit 151: Novartis AG - Key offerings
• Exhibit 152: Novartis AG - Segment focus

• 12.16 Pfizer Inc. 
• Exhibit 153: Pfizer Inc. - Overview
• Exhibit 154: Pfizer Inc. - Product / Service
• Exhibit 155: Pfizer Inc. - Key news
• Exhibit 156: Pfizer Inc. - Key offerings

• 12.17 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 159: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 160: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 161: Inclusions checklist
• Exhibit 162: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 163: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 164: Research methodology
• Exhibit 165: Validation techniques employed for market sizing
• Exhibit 166: Information sources

• 13.5 List of abbreviations 
• Exhibit 167: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio